We claim:

5

- 1. An isolated nucleic acid molecule comprising a member of the group consisting of:
 - (a) a nucleotide sequence that encodes a polypeptide having the amino acid sequence of FIG. 2;
 - (b) the complement of the nucleotide sequence of (a);
 - (c) a HBMYCNG gene or a complement of a
 HBMYCNG gene as contained in ATCC Deposit
 No. ;
 - (d) an isolated nucleic acid molecule comprising nucleotides 23 to 2011 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon;
 - (e) an isolated nucleic acid molecule comprising nucleotides 20 to 2011 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;
 - (f) An isolated nucleic acid molecule
 comprising the nucleotide sequence of FIG.
 1;
 - (g) A nucleic acid molecule comprising a nucleotide sequence encoding a deletion mutant of HBMYCNG or the complement of the nucleotide sequence of the deletion mutant of HBMYCNG;
 - (h) a nucleic acid molecule capable of hybridizing to and which is at least 95% identical to a nucleic acid molecule of
 (a), (b), (c), (d), (e), (f), or (g); and

15

10

20

25

30

- (i) An isolated nucleic acid molecule of (h),further comprising a label.
- An isolated nucleic acid molecule comprising a nucleotide sequence that hybridizes to the nucleic acid of claim 1 and encodes a naturally occurring HBMYCNG
 polypeptide.
- 3. An isolated nucleic acid molecule of claim 2 further comprising the nucleotide sequence linked uninterrupted by stop codons to a nucleotide sequence that encodes a heterologous protein or peptide.
 - 4. A recombinant vector containing the nucleotide sequence of claim 1.
- 20 5. A genetically engineered host cell containing the nucleotide sequence of claim 1.
- 6. The genetically engineered host cell of claim 5 containing the nucleotide sequence of claim 1 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that controls expression of the nucleotide sequence in a host cell.
- 30 7. A method of making an HBMYCNG polypeptide comprising the steps of:
 - (a) culturing the cell of claim 6 in an appropriate culture medium to produce an HBMYCNG polypeptide; and
- 35 (b) isolating the HBMYCNG polypeptide.

10

20

25


30

- 8. The method of claim 7, wherein the HBMYCNG polypeptide is HBMYCNG or a functionally equivalent derivative thereof.
 - 9. An antibody preparation which is specifically reactive with an epitope of an HBMYCNG polypeptide.
 - 10. A transgenic animal comprising the nucleic acid molecule of claim 1.
- 11. A substantially pure polypeptide comprising a 15 member of the group selected from:
 - (a) A substantially pure polypeptide encoded by the nucleic acid molecule of claim 1;
 - (b) A substantially pure human polypeptide, as depicted in FIG. 2;
 - (c) A substantially pure polypeptide which is at least 95% identical to the polypeptide as set forth in FIG. 2;
 - (d) A substantially pure polypeptide comprising amino acids 2 to 664 of SEQ ID NO:2, wherein said amino acids 2 to 664 comprise a polypeptide of SEQ ID NO:2 minus the start methionine; and
 - (e) A substantially pure polypeptide comprising amino acids 1 to 664 of SEQ ID NO:2.
 - 12. A fusion protein comprising a polypeptide of claim 11 and a second heterologous polypeptide.
- 35 13. A test kit for detecting and/or quantitating a wild type or mutant HBMYCNG nucleic acid molecule in a sample, comprising the steps of contacting the sample

20

25

35



- 14. A test kit for detecting and/or quantitating a 10 wild type or mutant HBMYCNG polypeptide in a sample, comprising the steps of contacting the sample with the antibody of claim 9; and detecting and/or quantitating a polypeptide-antibody complex as an indication of the presence or absence and/or amount of a wild type or 15 mutant HBMYCNG nucleic acid.
 - 15. A method for identifying compounds that modulate HBMYCNG activity comprising:
 - (a) contacting a test compound to a cell that expresses a HBMYCNG gene;
 - (b) measuring the level of HBMYCNG gene expression in the cell; and
 - (c) comparing the level obtained in (b) with the HBMYCNG gene expression obtained in the absence of the compound;

such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound that modulates HBMYCNG activity is identified.

- 30 16. A method for identifying compounds that modulate HBMYCNG activity comprising:
 - (a) contacting a test compound to a cell that contains a HBMYCNG polypeptide;
 - (b) measuring the level of HBMYCNG polypeptide or activity in the cell; and
 - (c) comparing the level obtained in (b) with the level of HBMYCNG polypeptide or

activity obtained in the absence of the compound;

such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound that modulates HBMYCNG activity is identified.

- 10 17. A method for identifying compounds that regulate ion channel-related disorders, comprising:
 - (a) contacting a test compound with a cell which expresses a nucleic acid of claim 1, and
- (b) determining whether the test compound modulates HBMYCNG activity.
- 18. A method for the treatment of ion channel-related disorders, comprising administering an 20 effective amount of a compound that increases expression of a HBMYCNG gene.
- 19. A pharmaceutical formulation for the treatment of ion channel-related disorders, comprising a compound25 that activates or inhibits HBMYCNG activity, mixed with a pharmaceutically acceptable carrier.
 - 20. A method for identifying compounds that modulate the activity of an ion channel comprising:
- (a) contacting a test compound to a cell that expresses a HBMYCNG gene and the ion channel, and measuring Ca+2 flux into the cell;
- (b) contacting a test compound to a cell that expresses a HBMYCNG gene but does not express the ion channel, and measuring Ca+2 flux into the cell; and

15

20


25

30

- (c) comparing Ca+2 flux obtained in (b) with the Ca+2 flux obtained in (a); such that if the level obtained in (b) differs from that obtained in (b), a compound that modulates ion channel activity is identified.
- 10 21. An isolated nucleic acid molecule consisting of a member of the group consisting of:
 - (a) a nucleotide sequence that encodes a polypeptide having the amino acid sequence of FIG. 2;
 - (b) the complement of the nucleotide sequence of (a);
 - (c) a HBMYCNG gene or a complement of a
 HBMYCNG gene as contained in ATCC Deposit
 No. ;
 - (d) an isolated nucleic acid molecule comprising nucleotides 23 to 2011 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon;
 - (e) an isolated nucleic acid molecule comprising nucleotides 20 to 2011 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;
 - (f) An isolated nucleic acid molecule
 comprising the nucleotide sequence of FIG.
 1;
 - (g) A nucleic acid molecule comprising a nucleotide sequence encoding a deletion mutant of HBMYCNG or the complement of the nucleotide sequence of the deletion mutant of HBMYCNG;

ļ.L





(i) An isolated nucleic acid molecule of (h), further comprising a label.

10

15

20

25

5

- 22. A substantially pure polypeptide consisting of a member of the group selected from:
 - (a) A substantially pure polypeptide encoded by the nucleic acid molecule of claim 1;
 - (b) A substantially pure human polypeptide, as depicted in FIG. 2;
 - (c) A substantially pure polypeptide which is at least 95% identical to the polypeptide as set forth in FIG. 2;
 - (d) A substantially pure polypeptide comprising amino acids 2 to 664 of SEQ ID NO:2, wherein said amino acids 2 to 664 comprise a polypeptide of SEQ ID NO:2 minus the start methionine; and
 - (e) A substantially pure polypeptide comprising amino acids 1 to 664 of SEQ ID NO:2.

30